high grade tumor (Gleason 9, 4+5)
Patient was initially treated with ADT + Abiraterone + Prednisone followed by treatment
with docetaxel. On further progression was offered molecular testing and was treated with
targeted agent, PARP inhibitor.
Following aspects of case are covered:
• Role of whole genome sequencing and precision medicine in the field of castration resistant prostate cancer (CRPC)
• PAPR inhibitors for the treatment of patients with BRCA 1/2 alteration after progression on androgen receptor targeting agents
• Liquid biopsy to overcome challenges of tissue analysis
Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
